Safety and Feasibility of Nivolumab-IRDye800CW in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC)
Vanderbilt-Ingram Cancer Center
Vanderbilt-Ingram Cancer Center
Eli Lilly and Company
NRG Oncology
Royal Marsden NHS Foundation Trust
VLP Therapeutics
H. Lee Moffitt Cancer Center and Research Institute
H. Lee Moffitt Cancer Center and Research Institute
Memorial Sloan Kettering Cancer Center
University of Chicago
Sanford Health
3B Pharmaceuticals GmbH
Bicara Therapeutics
Leap Therapeutics, Inc.
Providence Health & Services
University of Pittsburgh
Abramson Cancer Center at Penn Medicine
Revolution Medicines, Inc.